Skip to main content

Table 1 Clinical characteristic

From: Clinical characteristics of refractory mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy

Clinical information

Group I(81)

Group II (44)

P-value

General information

 Sex (female/male)

36/45

22/22

0.552

 Age, years

6.54 ± 3.03

7.61 ± 2.49

0.031

 Weight, kg

20.4 (16.4, 28.9)

27.2 (20.0, 33.5)

0.002

Clinical presentation n (%)

 Fever

81 (100%)

44 (100%)

1.00

 Cough

75 (92.6%)

43 (97.7%)

0.891

 Hypoxemia

6 (7.41%)

28 (63.6%)

0.000

 respiratory failure

0

2 (4.55%)

0.041

 Extra-pulmonary complications

18 (22.2%)

33 (75.0%)

0.007

 Thromboembolism

2 (2.47%)

2 (4.55%)

0.613

total fever duration, days

11 (8, 13)

13 (11, 15)

0.000

preadmission fever duration, days

7 (5, 8)

6 (4, 7)

0.329

fever duration at the time of CS treatmenta, days

1.95 ± 1.91

5.45 ± 2.76

0.000

Length of stay, days

8 (7, 10)

13.5 (11.3, 16)

0.000

Management

 Hormone dose, mg/kg/day

2 (1.5, 2)

10 (8.5, 10)

0.000

 Gamma globulin, n (%)

9 (11.1%)

17 (38.6%)

0.000

 Bronchoscopy, n (%)

57 (70.4%)

41 (93.2%)

0.000

 Plastic bronchitis, n (%)

14 (17.3%)

29 (65.9%)

0.000

  1. Data are presented as number (percentage), median (25th–75th percentile). Data are presented as mean ± SD (x ± s)
  2. aThe meaning of fever duration at the time of corticosteroids treatment is that fever days after starting corticosteroids therapy